Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II Trial of [212Pb]VMT-alpha-NET in GI NET and PPGL
NCT06427798Phase 2Recruiting
- Sponsor
- National Cancer Institute
- Start
- Feb 2025
- Primary completion
- Jul 2029
- Countries
- 1
01
Overview
A Phase 2 trial of VMT-α-NET in gastrointestinal neuroendocrine tumor, pheochromocytoma, Paraganglioma (PGL), sponsored by National Cancer Institute. Started Feb 2025; status: recruiting.
02
Drugs
VMT-α-NET
03
Conditions
gastrointestinal neuroendocrine tumorpheochromocytomaParaganglioma (PGL)
Beyond the preview
Go deeper on NCT06427798.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06427798.